Biggest News Aggregation in the World
📰 Support Program News

Page 41 - Support Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Support Program. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

FDA Approves Merck's KEYTRUDA® Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1

This Is the First Anti-PD-1 Combination Approved as First-Line Treatment for These Patients Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose ...
United States University Of Arizona Peter Dannenbaum Melissa Moody Roy Baynes Statement Of Merck Co Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science